Genmab A/S, GlaxoSmithKline (JOBS) Cancer Drug Arzerra Disappoints in Phase 3 Study

Published: Aug 20, 2009

Bookmark and Share

Reuters -- Disappointing clinical results sent shares in Danish biotechnology company Genmab tumbling 26 percent on Tuesday as investors questioned sales prospects for its key drug Arzerra in treating blood cancer.

Back to news